These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. Monés J; Biarnés M; Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111 [TBL] [Abstract][Full Text] [Related]
4. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol. Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577 [TBL] [Abstract][Full Text] [Related]
5. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617 [TBL] [Abstract][Full Text] [Related]
6. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment. Yeter DY; Dursun D; Bozali E; Ozec AV; Erdogan H J Fr Ophtalmol; 2021 Mar; 44(3):299-306. PubMed ID: 33608176 [TBL] [Abstract][Full Text] [Related]
7. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography. Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338 [TBL] [Abstract][Full Text] [Related]
8. TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Starr MR; Kung FF; Mejia CA; Bui YT; Bakri SJ Retina; 2020 Sep; 40(9):1665-1672. PubMed ID: 31725524 [TBL] [Abstract][Full Text] [Related]
9. Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration. Abdolrahimzadeh S; Gharbiya M; Formisano M; Bertini F; Cerini A; Pacella E Curr Eye Res; 2019 Sep; 44(9):1000-1005. PubMed ID: 30999772 [No Abstract] [Full Text] [Related]
10. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153 [TBL] [Abstract][Full Text] [Related]
11. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967 [TBL] [Abstract][Full Text] [Related]
12. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255 [TBL] [Abstract][Full Text] [Related]
13. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes. Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993 [TBL] [Abstract][Full Text] [Related]
15. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies. Dugel PU; Jhaveri CD; Chakravarthy U; Wykoff CC; Singh RP; Hamilton R; Weissgerber G; Mulyukov Z; Holz FG Retina; 2022 Mar; 42(3):511-518. PubMed ID: 34923515 [TBL] [Abstract][Full Text] [Related]
16. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
17. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis. Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059 [TBL] [Abstract][Full Text] [Related]
19. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692 [TBL] [Abstract][Full Text] [Related]
20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]